Delving into the Latest Updates on Denosumab Biosimilar(CuraTeQ) with Synapse

Overview

Basic Info

Drug Type

Biosimilar, Monoclonal antibody

Synonyms

Denosumab Biosimilar (Curateq Biologics Pvt Ltd.)

+ [1]

Target

RANKL

Action

inhibitors

Mechanism

RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors)

Therapeutic Areas

Endocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases

Active Indication

Osteoporosis, Postmenopausal

Inactive Indication-

Originator Organization

Curateq Biologics Pvt Ltd.

Active Organization

Curateq Biologics Pvt Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 143522H

The sequence is quoted from: *****

Sequence Code 94568L

The sequence is quoted from: *****

A Prospective, Randomized, Double Blind, Multicentric, Parallel Group Phase-III Clinical Study to Evaluate the Efficacy, Safety, Immunogenicity, Pharmacokinetics and Pharmacodynamics of BP16 Denosumab (60 mg/1ml single use Pre-filled Syringe) in Comparison to EU approved Prolia® (Denosumab, 60 mg/1ml single use Pre-filled Syringe) in Women with Postmenopausal Osteoporosis - NIL

Start Date26 Nov 2023

Sponsor / Collaborator

Curateq Biologics Pvt Ltd.

ACTRN12623000520639

/ CompletedPhase 1

A Randomized, Double-Blind, Parallel group, Comparative Phase I study for the assessment of Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of BP16 versus US licensed - Prolia® and EU approved - Prolia® Following a Single dose (60mg/mL) Subcutaneous Administration in Healthy Male Volunteers

Start Date26 Jun 2023

Sponsor / Collaborator

Curateq Biologics Pvt Ltd.

[+1]

100 Clinical Results associated with Denosumab Biosimilar(CuraTeQ)

Login to view more data

100 Translational Medicine associated with Denosumab Biosimilar(CuraTeQ)

Login to view more data

100 Patents (Medical) associated with Denosumab Biosimilar(CuraTeQ)

Login to view more data

3

Literatures (Medical) associated with Denosumab Biosimilar(CuraTeQ)

01 Jan 1982·OncologyQ4 · MEDICINE

Pilot Studies of Various Combinations of Dibromodulcitol, VP-16, and AMSA

Q4 · MEDICINE

Article

Author: Eagan, Robert T.

Pilot studies to obtain drug dosages for the combinations of dibromodulcitol (DBD) and BP-16, DBD and AMSA, and DBD, VP-16 and AMSA were carried out to levels of acceptable clinical toxicity. Myelosuppression was the dose-limiting toxicity in all combinations. While regressions were few in this group of heavily pretreated patients, we feel the drug combinations need further study in central nervous system, breast, and lung cancers.

Organic & Biomolecular ChemistryQ3 · CHEMISTRY

Enzyme-triggered delivery of chlorambucil from conjugates based on the cell-penetrating peptide BP16

Q3 · CHEMISTRY

Article

Author: Massaguer, Anna ; Planas, Marta ; González-Bártulos, Marta ; Feliu, Lidia ; Figueras, Eduard ; Ribas, Xavi ; Soler, Marta ; Costas, Miquel

The combination of the cell-penetrating peptide BP16 with the enzymatic cleavable sequence Gly-Phe-Leu-Gly constitutes a drug delivery system for the effective uptake and release of chlorambucil in cancer cells.

MoleculesQ3 · CHEMISTRY

A Bifunctional Peptide Conjugate That Controls Infections of Erwinia amylovora in Pear Plants

Q3 · CHEMISTRY

ArticleOA

Author: Bonaterra, Anna ; Francés, Jesús ; Caravaca-Fuentes, Pau ; Oliveras, Àngel ; Baró, Aina ; Planas, Marta ; Camó, Cristina ; Badosa, Esther ; Montesinos, Emilio ; Feliu, Lidia

In this paper, peptide conjugates were designed and synthesized by incorporating the antimicrobial undecapeptide BP16 at the C- or N-terminus of the plant defense elicitor peptide flg15, leading to BP358 and BP359, respectively. The evaluation of their in vitro activity against six plant pathogenic bacteria revealed that BP358 displayed MIC values between 1.6 and 12.5 μM, being more active than flg15, BP16, BP359, and an equimolar mixture of BP16 and flg15. Moreover, BP358 was neither hemolytic nor toxic to tobacco leaves. BP358 triggered the overexpression of 6 out of the 11 plant defense-related genes tested. Interestingly, BP358 inhibited Erwinia amylovora infections in pear plants, showing slightly higher efficacy than the mixture of BP16 and flg15, and both treatments were as effective as the antibiotic kasugamycin. Thus, the bifunctional peptide conjugate BP358 is a promising agent to control fire blight and possibly other plant bacterial diseases.

100 Deals associated with Denosumab Biosimilar(CuraTeQ)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	M05BX04	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoporosis, Postmenopausal	Phase 3	India	Curateq Biologics Pvt Ltd.	26 Nov 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.


No Data

Denosumab Biosimilar(CuraTeQ)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation